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S U M M A R Y
Background: The 2009 inﬂuenza pandemics underscored the need for effective vaccines to block the
spread of inﬂuenza virus infection. Most live attenuated vaccines utilize cold-adapted, temperature-
sensitive virus. An alternative to live attenuated virus is presented here, based on microRNA-induced
gene silencing.
Methods: In this study, miR-let-7b target sequences were inserted into the H1N1 genome to engineer a
recombinant virus – miRT-H1N1. Female BALB/c mice were vaccinated intranasally with the miRT-H1N1
and challenged with a lethal dose of homologous virus.
Results: This miRT-H1N1 virus was attenuated in mice, while it exhibited wild-type characteristics in
chicken embryos. Mice vaccinated intranasally with the miRT-H1N1 responded with robust immunity
that protected the vaccinated mice from a lethal challenge with the wild-type 2009 pandemic H1N1
virus.
Conclusions: These results indicate that the inﬂuenza virus containing microRNA response elements
(MREs) is attenuated in vivo and can be used to design a live attenuated vaccine.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Inﬂuenza virus infection represents a serious threat to public
health. Each year, it affects a signiﬁcant portion of the population
worldwide. The spread of a novel 2009 inﬂuenza A H1N1 virus
infection reminded us of public vulnerability to new viral strains.
The development of a new generation of vaccines is urgently
needed.1–3
Of all the vaccination strategies available, vaccination using live
attenuated virus is the most effective method of immunization
because the vaccinated virus is able to infect and replicate even
though the replication efﬁciency is compromised. Consequently, it
effectively stimulates all immune responses and offers robust
protection against viral infection.4 Most live attenuated vaccines
utilize virus that possesses a cold-adapted, temperature-sensitive
phenotype. Inducing this temperature-sensitive phenotype is
time-consuming.5 Virus can be attenuated by other mechanisms.* Corresponding authors.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).For instance, microRNA (miRNA) regulates viral replication
through repression of translation.6 The engineering of a tissue-
speciﬁc miRNA response element (MRE) in viral mRNAs has been
used recently to restrict viral tissue tropism, including that of
coxsackievirus, vesicular stomatitis virus, poliovirus, and dengue
virus.7–10 Incorporation of miRNA target sequences into the
nucleoprotein (NP) segment,11,12 or into the hemagglutinin (HA)
segment,13 has been reported to result in attenuated inﬂuenza A
virus.
It was reasoned that such technology could be used to generate
live attenuated inﬂuenza virus for vaccine production. The lungs
are the main target organ of inﬂuenza viral infection. Let-7b
expression is abundant in pulmonary tissues, as shown by the
Miranda online database (http://www.microrna.org/) and other
references.14 In a previous study, the miR-let-7b target sequence
was inserted into a 2009 pandemic H1N1 virus genome (A/
Nanjing/NJU-108/2009) to engineer a recombinant virus – miRT-
H1N1. It was demonstrated that this recombinant virus was unable
to infect human bronchial epithelial cells (HBE cells) that express a
high level of corresponding miRNA-let-7b.15 Upon production of
miRNA-let-7b, the viral replication was restricted and the virus
became attenuated.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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miRT-H1N1 virus produces an attenuated phenotype in vivo. The
viral replication efﬁciency, elicited immune responses, and
protective efﬁcacy were investigated in a mouse model immunized
with the MRE-containing inﬂuenza A virus.
2. Materials and methods
2.1. Viruses
The inﬂuenza A H1N1 virus A/Nanjing/108/2009 (WT-H1N1)
was initially isolated from a Chinese patient in 2009.16 The
genomic sequences were deposited in GenBank (accession
numbers JQ173100 through JQ173107). The genomic segments
of WT-H1N1 were separately cloned into a plasmid, pDP2000,
resulting in various cDNA constructs of PB2, PB1, PA, HA, NP, NA, M,
and NS, respectively. A plasmid encoding a mutated PB1 segment
was constructed by incorporating MREs of let-7b into the open
reading frame (site of 83–107 bp).15 Three amino acids were
changed in the let-7b target sequence. The mutated virus (miRT-
H1N1) was constructed by plasmid-based reverse genetics. A
control virus (scbl-H1N1) was designed, containing additional
mutations in addition to the three mutated amino acids engineered
in miRT-H1N1. The control virus was used to distinguish
phenotypic differences in the presence or absence of miRNA
binding. The viruses generated through transfection were then
expanded through infection of speciﬁc-pathogen free (SPF) chicken
embryos (Qian YuanHao Biological Co. Ltd, Nanjing, China). Virus
containing allantoic ﬂuid was collected, aliquoted, and stored at
80 8C until use. The method developed by Reed and Muench was
used to determine the 50% tissue culture infectious dose (TCID50)
for each virus.17 All procedures involving handling of the WT and
mutant viruses were performed in a biosafety level 3+ animal
facility certiﬁed by the Academy of Military Medical Sciences
(AMMS).
2.2. Experimental infection of mice
Six-week-old female BALB/c mice (at the Laboratory Animal
Center of Jinling Hospital, Nanjing, China) were placed under
chloral hydrate anesthesia and infected intranasally with 105
TCID50 of WT-H1N1, miRT-H1N1, or scbl-H1N1 virus in 50 ml
phosphate-buffered saline (PBS). Animals were weighed daily and
their mortality was monitored for 14 days after infection. Four
mice per group were euthanized on days 3 and 5 post-infection and
lung tissues were collected for viral titration. Tissue homogenate
was clariﬁed by low-speed centrifugation, and titrated in 96-well
culture plates with a seeding monolayer of Madin–Darby canine
kidney (MDCK) cells.18 Titers were expressed as the TCID50/g
log10. MLD50, the dose required to kill 50% of mice, was determined
using previously described methods.19
2.3. Evaluation of immunogenicity in mice
Six-week-old female BALB/c mice were primed with 50 ml of
PBS (mock-immunized group) or 105 TCID50 of miRT-H1N1 virus
intranasally on day 0, and boosted with the same dose on day
28. Blood samples were collected for antibody detection on days
28 and 42 post-vaccination. Meanwhile, six mice per group were
euthanized 2 weeks after the second vaccination. Trachea–lung
and nasal washes were harvested for the detection of mucosal
sIgA.
IgG antibodies in serum and of IgA in trachea–lung and nasal
washes were detected by ELISA.20 Brieﬂy, plates were ﬁrst coated
with puriﬁed H1N1 virus. The HA-coated plates were incubated
with test samples, and the bound antibodies were detected withhorseradish peroxidase (HRP)-conjugated goat anti-mouse immu-
noglobulin. Wells with an optical density (OD) value >0.2 at
405 nm were considered positive.
A microneutralization (MN) assay was used to determine
neutralizing antibody titers in serum samples.21 Heat-inactivated
serum was serially diluted two-fold starting from a 1:20 dilution.
Neutralizing antibody titers were expressed using the reciprocal of
the highest dilution at which the infectivity of 100 TCID50 of the
WT-H1N1 virus was completely neutralized. An absence of viral
cytopathic effect at day 4 was considered complete neutralization.
A hemagglutination inhibition (HI) assay was performed after
the serum was treated with receptor-destroying enzyme (RDE;
Denka Seiken Co. Ltd, Tokyo, Japan) and incubated with 0.5%
chicken red blood cells (CRBCs).22 Serum viruses were diluted with
PBS to contain four agglutinating units.
For the detection of cytokines, single spleen cell suspensions
were prepared and stimulated with puriﬁed H1N1 virus at a
concentration of 5  106 cells/ml on day 28 post-vaccination.23
Culture supernatants were harvested for the detection of
interleukin 4 (IL-4) and interferon gamma (IFN-g) by ELISA after
3 days of culture.
2.4. Analysis of efﬁcacy against WT-H1N1 challenge
Mice were challenged intranasally with 100 LD50 of WT-H1N1
virus at 42 days post-vaccination. Mock-infected control mice only
received 50 ml PBS. Challenged mice were monitored and their
symptoms, body weight, and survival were recorded for 14 days.
Three mice per group were euthanized and the lung tissues were
harvested on day 5 post-challenge. The parafﬁn-embedded tissues
were sliced for hematoxylin–eosin (HE) staining. The histopatho-
logical score (HPS) was determined by a pathologist who was
blinded to the sample IDs. The HPS system, consisting of a numerical
score ranging from 0 to 26, has been described by Cimolai et al.24
RNA was extracted from lung tissues using the RNeasy Kit
(Qiagen). Quantitative RT-PCR was performed with a 7300 Real
Time PCR System (Applied Biosystems). IL-6, IFN-b, and tumor
necrosis factor alpha (TNF-a) mRNA levels of gene expression were
normalized to levels of b-actin for each sample. The difference in
signal was determined using the DDCt cycle threshold calculation.
2.5. Statistical analysis
All quantitative data were calculated as the mean  standard
deviation (SD). The antibody titers for each group were plotted and
error bars extended to 95% conﬁdence upper limits. Analysis of variance
(ANOVA) and/or the Student’s t-test were used for comparisons. A
p-value of <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Generation of mutant miRT-H1N1 virus and infection of chicken
embryos
A 2009 pandemic H1N1 mutant virus (miRT-H1N1) carrying
miR-let-7b target sequences was generated successfully. Ten-day-
old embryonated chicken eggs were inoculated with WT-H1N1,
miRT-H1N1, or scbl-H1N1 virus to amplify them. Allantoic ﬂuid
was harvested on day 2 after infection and titers were determined
for each of the three strains. The results showed that miRT-H1N1
virus replicated as well as WT-H1N1 virus (Figure 1).
3.2. The miRT-H1N1 virus was attenuated in mice
First, the respective MLD50 was determined for WT-H1N1, scbl-
H1N1, and miRT-H1N1 viruses in mice. The MLD50 of WT-H1N1
Figure 1. Growth properties of the recombinant viruses in chicken embryos. Viral
titers of WT-H1N1 and MRE-containing H1N1 inﬂuenza A virus in infected 10-day-
old embryonated chicken eggs. The viral titer was determined by TCID50 using
MDCK cells.
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similar MLD50 value to wild-type, as expected (10
5.38 TCID50). In
contrast, the miRT-H1N1 virus was not lethal against any mice at
this dose, resulting in increased doses (MLD50 >10
7 TCID50).
Next, the virus replication level in mice was determined. WT-
H1N1 and scbl-H1N1 replication produced high viral titers in lungs
of infected animals (105.37 TCID50/g and 10
5.49 TCID50/g on day
3 post-inoculation, respectively). The replication of miRT-H1N1, by
contrast, was restricted to103.50 TCID50/g. All viruses were detected
at relatively low titers in the respiratory system on day 5 post-
inoculation. The miRT-H1N1 virus grew more slowly than WT-
H1N1 and scbl-H1N1 in lungs (Table 1).
RNA sequences of miRT-H1N1 virus isolated from the lungs of
infected mice were also analyzed. Sequence analysis showed no
mutations in the miR-let-7b target region (data not shown).
3.3. Antibody responses to miRT-H1N1 immunization in mice
All mice immunized with miRT-H1N1 virus showed appreci-
able neutralizing activity against the homologous WT-H1N1 virus
(Figure 2B). Similarly, the levels of HI antibodies were higher in
mice immunized with miRT-H1N1 virus than those treated with
the PBS control (Figure 2A). The geometric mean titer (GMT) of HI
antibody against the WT-H1N1 virus was 403 at 28 days after the
ﬁrst immunization, which increased sharply to 2032 at 2 weeks
after the second immunization (42 days after the ﬁrst immuniza-
tion) (Figure 2A).
The IgG antibody response against the WT-H1N1 virus in the
vaccinated mice was analyzed next. Similarly, the IgG antibody
titers in serum were correspondingly increased with the changes inTable 1
Replication of viruses in mice
Virus Infection dose
(TCID50/mouse)
Virus titer (mean log10 TCID50/g  SD)a
Day
3 post-inoculation
Day 5
post-inoculation
Lungs Lungs
WT-H1N1 105 5.37  0.22b 3.71  0.24d
scbl-H1N1 105 5.49  0.33c 3.49  0.29e
miRT-H1N1 105 3.50  0.1b,c 1.5  0.2d,e
TCID50, 50% tissue culture infectious dose; SD, standard deviation.
a Mice were infected with 105 TCID50 of WT-H1N1, scbl-H1N1, or miRT-H1N1
virus. Tissue samples were collected from four mice per group on the indicated days
post-inoculation. Virus titers were determined in MDCK cells.
b,c,d,eViral titer differences between two groups were tested for statistical
signiﬁcance using ANOVA (p < 0.05).HI titers. Mice developed robust IgG antibodies (GMT 905; 28 days
post-ﬁrst immunization). A much stronger IgG antibody response
(GMT 2873) appeared after the booster (42 days post-immuniza-
tion) (Figure 2C). Furthermore, immunization with the miRT-H1N1
virus induced higher levels of sIgA in trachea–lung (GMT 64) and
nasal washes (GMT 16) compared with the control group
(Figure 3).
Additionally, stronger IL-4 and IFN-g production was detected
in spleen cells isolated from mice immunized with miRT-H1N1
virus compared with mock-immunized controls (Figure 4).
3.4. Protective efﬁcacy of miRT-H1N1 virus immunization in mice
All animals vaccinated with miRT-H1N1 were fully protected
against the lethal H1N1 infection with 100 MLD50 of WT-H1N1
virus, as demonstrated by the absence of signs of disease and
limited weight loss after challenge compared with the mock-
vaccinated animals (Figure 5, A and B). In contrast, mock-
vaccinated mice succumbed to challenge within 8 days post-
challenge. Symptoms included rough fur, quietness, and loss of
appetite and weight in all of the control mice.
Virus titers were titrated in the lungs of the challenged mice on
days 3 and 5 post-challenge (Table 2). All samples in the mock-
immunized control group showed high viral titers on both days.
The miRT-H1N1 virus-immunized mice group showed signiﬁcant-
ly lower or undetectable levels of WT virus in the lungs at 3 and
5 days post-challenge than the mock-vaccinated mice (Table 2).
The lung histopathology of mice challenged with WT-H1N1
virus was analyzed at 5 days post-challenge. A severe pneumonia
pathology, with alveolar collapse, inﬂammatory inﬁltrates, necro-
tizing bronchitis, and extensive hemorrhagic lesions, was detected
in the lungs of the mock-vaccinated group (Figure 6A). By contrast,
only mild histopathological alterations were detected in the lungs
of miRT-H1N1 vaccinated mice. The HPS was signiﬁcantly lower in
miRT-H1N1 vaccinated mice than in the control mice (Figure 6B).
3.5. miRT-H1N1 immunization reduced the inﬂammatory response
upon inﬂuenza challenge
There is innate immunity against inﬂuenza virus infection of
the mucosa. The levels of IFN-b and the pro-inﬂammatory
cytokines IL-6 and TNF-a were therefore examined in the lung
tissue following H1N1 challenge, as markers of the innate immune
response. Lower levels of IFN-b, IL-6, and TNF-a were detected on
days 3 and 5 following challenge in the miRT-H1N1 vaccinated
group compared with the PBS control groups (Figure 7). The lower
inﬂammation was accompanied by lower viral titers and reduced
pathology in the miRT-H1N1 vaccinated mice.
4. Discussion
Approximately 14 700 people in more than 209 countries died
as a result of the 2009 inﬂuenza A (H1N1) virus pandemic
infection.25 Such a widespread infection affecting a large number
of the population reminds us of the importance of effective
vaccination of the mass population. Unfortunately, the current
vaccine production scheme impedes such efforts. For instance, it is
time-consuming to prepare live attenuated virus through the cold-
adaption process. An innovative process to introduce attenuated
virus is urgently needed.
A pandemic H1N1 2009 virus (A/Nanjing/NJU-108/2009) was
isolated from the swab sample of an outpatient febrile child at
Nanjing Children’s Hospital, Nanjing, China during the pandemic in
2009. A reassorted live attenuated inﬂuenza vaccine (LAIV) for
H1N1 (miRT-H1N1) was generated after MREs of microRNA-let-7b
were inserted into the polymerase (P) gene PB1 segment of
Figure 2. Humoral antibody responses in mice immunized with miRT-H1N1 virus. Serum samples were collected 4 weeks after the ﬁrst immunization (on day 28 post-
immunization) and 2 weeks after the second immunization (on day 42 post-vaccination). Serum antibody titers were determined by hemagglutination inhibition (HI) and
microneutralization assays. The anti-inﬂuenza IgG levels in sera were measured by ELISA. (A) HI, and (B) neutralizing antibody responses to the miRT-H1N1 viruses after
vaccination with105 TCID50 of the miRT-H1N1 viruses. (C) IgG levels in sera. (*p < 0.05, compared with the negative PBS control group; n = 6 in each group.)
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efﬁcacy of immunization with this mutant virus, which was
attenuated via miR-let-7b mechanism, was investigated through
infection in mice. MicroRNA-let-7b is expressed abundantly in
lung tissue and airway epithelial cells, but sparsely in HEK293 cells
and chicken embryos.26,27 Previous data from our laboratory
demonstrated that the replication of miRT-H1N1 virus was
suppressed in HBE cells expressing high levels of miR-let-7b,
while it maintained wild-type characteristics in HEK293 cells
expressing low levels of miR-let-7b. Further, it was found that the
growth of miRT-H1N1 virus was comparable to WT-H1N1 virus in
MDCK cells or embryonated hen eggs in which let-7b isFigure 3. Mucosal antibody responses in mice immunized with miRT-H1N1 virus. Trach
sIgA levels in nasal washes, (B) sIgA levels in trachea–lung washes. (*p < 0.05, comparinefﬁciently expressed (Figure 1). These results demonstrate that
attenuation of this virus is let-7b-dependent.
Whether attenuation of miRT-H1N1 virus could also be
introduced in vivo was investigated in the present study. It is
well known that several species of laboratory animals, including
mice and ferrets, are susceptible to inﬂuenza virus infection and
may serve as animal models. The study of pathogenesis and
evaluation of efﬁcacy of inﬂuenza vaccines are frequently carried
out in mice, particularly the BALB/c strain,28 with lungs expressing
high levels of let-7b. BALB/c mice were selected for this study.
Consistent with previously published studies,29,30 the present
results showed that wild-type A/Nanjing/NJU-108/2009ea–lung and nasal washes were collected 2 weeks after the second vaccination. (A)
ed with the negative PBS control group; n = 6 in each group.)
Figure 4. Cytokine levels in lung alveolar ﬂuid of vaccinated mice as determined by ELISA. Mice were primed on day 0 and then boosted on day 28 with PBS or miRT-H1N1
virus in a 50-ml volume, and the single spleen cell suspensions were stimulated with recombinant HA (rHA) on day 14 post-boost. Culture supernatants were harvested after
3 days and cytokines were detected. (A) Interleukin 4 (IL-4) concentration, (B) interferon gamma (IFN-g). (*p < 0.05, compared with the negative PBS control group; n = 3 in
each group.)
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severe pathological changes in the lungs of infected mice (Table 1).
However, the replication of miRT-H1N1 virus was compromised
and the miRT-H1N1 virus was attenuated and not lethal in all mice.
It was also found that attenuation was a result of interference
mediated by the endogenous miRNA-let-7b, which binds to MREs
carried by miRT-H1N1, resulting in suppression of miRNA
repression.
Although MRE-based attenuation is a rational approach to the
development of live attenuated vaccines, reversion of live
attenuated vaccine virus into a virulent phenotype is still aFigure 5. Protection of miRT-H1N1 virus-immunized mice from homologous H1N1
virus challenge. Mice were immunized with miRT-H1N1 virus, or PBS as a negative
control. They were then challenged with 100 LD50 of WT-H1N1 virus on day
42 post-immunization. (A) Weight change caused by WT-H1N1 virus challenge, (B)
mouse survival rate following the challenge with WT-H1N1 virus (n = 6 in each
group).potential risk. Virus escape from miRNA-mediated suppression has
been described, which can occur through deletions or mutations
within the region of the miRNA target sequence.31–33 However, no
escape mutants were observed in vivo in the present study. These
results demonstrate the genomic stability of miRT-H1N1 virus. To
prevent reversion and enhance safety, multiple miRNAs targeting
conserved viral sequences need to be combined.13,34
Strong immunity against inﬂuenza virus infection can be
generated with either inactivated or live attenuated inﬂuenza
vaccine. There are several advantages of live attenuated vaccine
over inactivated vaccine. Intranasal administration of live attenu-
ated inﬂuenza virus vaccines is accompanied by robust mucosal
immunity and cellular responses, which offer effective and longer-
lasting protection.35,36
In this study, it was successfully shown that immunization with
two doses of miRT-H1N1 live attenuated vaccine induced robust
humoral and mucosal immune responses. The immunized mice
produced higher speciﬁc IgG and IgA levels and were fully protected
against homologous WT-H1N1 virus challenge (Figures 2 and 3).
Mucosal immunity consisting of mucosal IgA, which binds and
neutralizes incoming viruses, is critical to protection against early
inﬂuenza infection.37 Immunization with live attenuated inﬂuenza
virus induces cell-mediated immunity, which interacts with B cells,
possibly via helper T cells or via cytotoxic T cells. Therefore, cell-
mediated immunity further contributes to a stronger mucosal
antibody response.38 This is supported by the appreciable produc-
tion of IFN-g and IL-4 in spleen cells (Figure 4), a conﬁrmation that
the miRT-H1N1 virus was able to elicit both Th-1 and Th-2
responses. An impact on innate immunity was also detected. The
expression of inﬂammatory cytokines was reduced in the lungs ofTable 2
Viral replication in immunized mice after challenge
Virus Virus titer (mean log10 TCID50/g  SD)a
Day 3 post-challenge Day 5 post-challenge
Lungs Lungs
PBS 5.13  0.47b 3.8  0.5
miRT-H1N1 1.53  0.68b ND
TCID50, 50% tissue culture infectious dose; SD, standard deviation; PBS, phosphate-
buffered saline; ND, not detected; LD50, dose required to kill 50% of mice.
a Three BALB/c mice per group were immunized intranasally with 105 TCID50 of
the miRT-H1N1 virus or PBS (50 ml per mouse). The immunized mice were
challenged intranasally with 100 LD50 WT-H1N1 virus at 4 weeks post-
immunization.
b Viral titer differences between two groups were tested for statistical
signiﬁcance using the Student’s t-test (p < 0.05).
Figure 6. Histopathology of infected lungs on day 5 post-challenge. (A) Pathological ﬁndings in mice: (a) lungs of control mice showing normal bronchioles and alveoli (HE
200); (b) lungs from mice vaccinated with miRT-H1N1 displaying mild histopathological lesions, including inﬂammatory inﬁltration and mild hemorrhage (with alveoli and
airways indistinguishable from those of control mice) (HE 200); (c) mock-vaccinated mice showing a severe histopathology characterized by extensive hemorrhagic lesions,
necrotizing bronchitis, inﬂammatory inﬁltration, and alveolar collapse (HE 200). (B) HPS of lung sections at 5 days post-challenge (*p < 0.05, compared with the negative
PBS control group; n = 3 in each group).
Figure 7. miRT-H1N1 virus vaccination reduces inﬂammatory cytokines in the lungs following inﬂuenza challenge. Mice were administered miRT-H1N1 virus or PBS. On day
42 post-vaccination, mice were challenged intranasally with 100 LD50 WT-H1N1 virus. On days 3 to 5 post-vaccination, lungs were harvested; cDNA was prepared and real-
time PCR was performed for (A) IL-6, (B) TNF-a, and (C) IFN-b (*p < 0.05, n = 6 in each group).
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group after WT-H1N1 virus challenge. The immune response to
inﬂuenza A infection includes an initial innate as well as adaptive
immune response, with T cell inﬁltrates in the lungs.39 Thus, the
present results indicate that both innate and adaptive responses
were generated with the miRT-H1N1 vaccination.
It was found that the miRT-H1N1 virus replication is let-7b-
dependent. This feature allows efﬁcient virus production in
chicken embryos and direct use as live vaccine, which can be
attenuated once the infection is established in vivo.
In summary, the miRT-H1N1 elicited robust immunity in mice
and protected the immunized mice from infection with homolo-
gous H1N1 viruses. These results prove the principle that MRE-
containing inﬂuenza attenuated virus (miRT-H1N1) can be used as
a live attenuated vaccine against pandemic viruses. Further studies
including investigations of cross-protective immunity and com-
parisons of efﬁcacy with currently approved live vaccines in mice,
are warranted.
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